Calcium channel blockers should generally be avoided in patients with heart failure with reduced ejection fraction (HFrEF) since they provide no functional or mortality benefit and some first generation agents may worsen outcomes [ 1 ]
Drugs may cause or exacerbate HF by causing direct myocardial toxicity; by negative inotropic, lusitropic, or chronotropic effects; by exacerbating hypertension; by
Atrial fibrillation (AF) is common among patients with heart failure (HF)
INTRODUCTION
Precautions
if you are receiving an intravenous beta-blocker (such as atenolol, metoprolol, or propranolol)
Purpose The 2021 European Society of Cardiology guidelines on acute and chronic heart failure (HF) recommend that non-dihydropyridine calcium channel blockers (NDCC) should be avoided in patients with HF with reduced ejection fraction
The clinical experience with verapamil and diltiazem in patients with heart failure is at present limited
They may be used if you have diastolic heart failure or hypertrophic cardiomyopathy
Mild symptoms of cardiac failure should be under control, if possible, prior to initiating diltiazem therapy
loss of
An acute study of oral diltiazem in patients with impaired Calcium channel blockers may be used to treat heart failure caused by high blood pressure when other medications to lower blood pressure do not work
Diltiazem can potentially worsen
Diltiazem is used to treat high blood pressure and to control angina (chest pain)
Drug-induced exacerbation or decompensation of established HF is a
1 What was initially thought to result from LV diastolic dysfunction alone, is now